NCT00525824
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
See it on ClinicalTrials.gov ↗833 people
45%
55%
375 womenmiddle line = equal numbers458 men
- Phase
- PHASE3
- Paid for by
- AstraZeneca
- Finished
- 2008-09
- Health conditions
- Hypercholesterolemia, Coronary Heart Disease, Atherosclerosis
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 62.0 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“a myocardial infarction, recent episode of unstable angina, myocardial revascularisation \[percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG) surgery or another revascularisation procedure\] or a tran…”
Study titles and rules are shown in their original English.